

1 **Title: Prevalence of asymptomatic glioma and implications for survival**

2 Paula Province Warren<sup>1</sup>, Mina Lobbous<sup>1</sup>, Noah C. Peeri<sup>2</sup>, Zachary J. Thompson<sup>3</sup>, Reid C.  
3 Thompson<sup>4</sup>, Jeffrey J. Olson<sup>5</sup>, Renato V. LaRocca<sup>6</sup>, Sajeel A. Chowdhary<sup>7</sup>, Mark D. Anderson<sup>8</sup>,  
4 Michael A. Vogelbaum<sup>9</sup>, James M. Markert<sup>10</sup>, Louis B. Nabors<sup>1</sup>, and Kathleen M. Egan<sup>2\*</sup>

5 <sup>1</sup>Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL 35294

6 <sup>2</sup>Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute,  
7 Tampa FL, 33612

8 <sup>3</sup>Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research  
9 Institute, Tampa FL, 33612

10 <sup>4</sup>Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN  
11 37232

12 <sup>5</sup>Department of Neurosurgery, Emory School of Medicine, Atlanta, GA 30322

13 <sup>6</sup>Norton Cancer Institute, Louisville, KY 40202

14 <sup>7</sup>Neuro-Oncology Program, Lynn Cancer Institute, Boca Raton, FL 33486

15 <sup>8</sup>Department of Neurology, the University of Mississippi Medical Center, Jackson, MS 39216

16 <sup>9</sup>Department of Neuro-oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL,  
17 33612

18 <sup>10</sup>Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294

19

20 **\*To whom correspondence should be addressed:**

21 Kathleen M. Egan, ScD

22 Department of Cancer Epidemiology

23 Moffitt Cancer Center

24 12902 Magnolia Drive, Tampa, FL 33612

25 E-mail: [kathleen.egan@moffitt.org](mailto:kathleen.egan@moffitt.org)

26

27 **Short Title: Patient Survival in Asymptomatic Glioma**

28 **Key Words:** glioma; incidentaloma; asymptomatic; epidemiology

29

30

31

32 **Abstract**

33

34 **Background** - Brain tumors can present as focal neurologic deficits (reflecting the tumor  
35 location) or generalized symptoms due to increased intracranial pressure. Occasionally, brain  
36 tumors can be found incidentally in asymptomatic patients or in patients with unrelated  
37 symptoms who undergo brain imaging. The term incidentaloma is used to refer to these imaging  
38 abnormalities.

39

40 **Objective** - The object of this study was to examine the prevalence and correlates of  
41 asymptomatic glioma in a large epidemiological study of brain tumors.

42

43 **Methods** - The analysis was based on a large series of patients with glioma (N = 1989) enrolled  
44 in a multicenter clinic-based epidemiologic study between 2005 and 2017. Patients were  
45 considered asymptomatic from the tumor, and thus as having an incidentally detected glioma  
46 (IDG), if the tumor was diagnosed during workup of injury or unrelated medical condition.

47

48 **Results** - A total of 32 of 1989 (1.6%) patients were asymptomatic at diagnosis. The leading  
49 indication for brain imaging in IDG was non-workplace injuries followed by medical workup for  
50 unrelated conditions. IDG was more prevalent in patients younger than 50 years of age (2.6% vs  
51 1.0%). IDG was also more common in patients with low grade gliomas (4.7% for WHO grade II  
52 and 1.5% for WHO grade III) vs glioblastomas (0.6% in WHO grade IV).

53

54 **Conclusion** - The present data suggest that gliomas may be found incidentally, especially among  
55 low grade gliomas. Studies of IDG may be useful as a proxy for early detection of tumor as a  
56 means to improve patient survival.

57

58

59

60

61

## 62 **Introduction**

63 The majority of patients with brain tumors present with either focal or generalized symptoms.  
64 Common presenting symptoms include seizures, symptoms of increased intracranial pressure,  
65 like headache and/or double vision, or focal neurologic deficits that depend on the intracranial  
66 location of the tumor <sup>1</sup>. Some patients, however, are asymptomatic at the time of presentation  
67 and have tumors that are incidentally discovered <sup>2</sup>. An “incidentaloma” is defined as an imaging  
68 abnormality that is detected by chance in patients who undergo imaging for an unrelated medical  
69 issue <sup>3,4</sup>. There has been a rapid rise in incidentaloma detection due to the increase in the number  
70 of imaging scans performed as well as improvement in imaging resolution. Common reasons for  
71 patients to undergo screening brain scans include trauma or medical workup for an unrelated  
72 condition. A 2009 systematic review of 16 studies in 19,559 patients reported the prevalence of  
73 incidental neoplastic brain findings in MRI studies to be 0.7%, with the prevalence of glioma at  
74 0.05% <sup>5</sup>. Diffuse low-grade glioma may be radiologically detectable but clinically silent for more  
75 than a decade <sup>6</sup>.

76 Advances in molecular profiling and in the understanding of gliomagenesis has allowed for  
77 improved diagnostic accuracy and better prognostic markers <sup>7,8</sup>. Although current  
78 recommendations support early surgical resection for low-grade gliomas <sup>9-13</sup>, management of  
79 asymptomatic incidentally diagnosed gliomas remains a matter of debate. There are multiple  
80 studies supporting moving away from the “watchful waiting” approach to earlier therapeutic  
81 strategies <sup>14-18</sup>. Pallud *et al* reported that incidental grade II gliomas were progressive in all cases  
82 and transformed to symptomatic grade II gliomas at a median interval of 48 months after  
83 radiological discovery and had malignant transformation at a median interval of 5.7 years after  
84 radiological diagnosis <sup>4,19</sup>. In addition, the identification of an IDG offers insight into the natural  
85 history of the disease prior to the time of neurological presentation.

## 86 **Subjects and Methods**

### 87 **Study Population**

88 The study population was comprised of 1,989 patients with a recent diagnosis of primary glioma  
89 (ICD9/10: 191, C71), including glioblastoma (9440-9441) and WHO (World Health  
90 Organization) grade II and III gliomas (9382, 9400-01, 9410-11, 9420, 9424-25, 9450-9451)<sup>20,21</sup>

91 , enrolled in an epidemiologic study of glioma<sup>22</sup> (“GliomaSE”) between 2005 and 2017. Patients  
92 were identified at neuro-oncology and neuro-surgery clinics at major medical centers in the  
93 Southeastern United States including Moffitt Cancer Center in Tampa, Florida; Kentuckiana  
94 Cancer Center (now Norton Cancer Institute) in Louisville, Kentucky; University of Mississippi  
95 Medical Center in Jackson, Mississippi; Emory University in Atlanta, Georgia; University of  
96 Alabama at Birmingham in Birmingham, Alabama; Morton Plant Hospital in Tampa, Florida;  
97 Vanderbilt University Medical Center in Nashville, Tennessee; Florida Hospital in Orlando,  
98 Florida; and Boca Raton Regional Hospital in Boca Raton, Florida). The study was approved by  
99 Investigational Review Committees at each participating center and all subjects provided written  
100 informed consent. Clinical data including presenting signs and symptoms were collected from  
101 neuro-oncology reports. Cause of death and follow-up for vital status were obtained through  
102 review of medical records, hospital registries, and a search of the National Death Index.

### 103 **Symptoms at Presentation**

104 Medical records for all patients were reviewed for first signs and symptoms of tumor  
105 presentation. Symptoms included headache, change in vision or hearing, focal weakness or  
106 numbness, memory loss, personality changes, speech difficulties, dizziness or loss of balance,  
107 gait or walking difficulties, confusion, and seizure. Patients were considered asymptomatic if the  
108 tumor was diagnosed incidentally during work-up for an injury or other non-related medical or  
109 surgical conditions. Neuro-oncology notes for each suspected IDG were reviewed by a board-  
110 certified neuro-oncologist (PPW). Cases in which events surrounding diagnostic neuroimaging  
111 were potentially related to early manifestations of the tumor (for example, a fall with head injury  
112 preceded by apparent seizure) were excluded from the IDG category.

### 113 **Statistical Analysis**

114 Associations between symptom status at presentation and demographic and clinical factors were  
115 assessed with Monte-Carlo estimates of exact *chi-square* test p-values. Logistic regression was  
116 used to estimate Odds Ratios (OR) and 95% Confidence Intervals (CI) relating clinical factors to  
117 IDG. Multivariable models included terms for tumor grade (Glioblastoma WHO grade IV, WHO  
118 grade III, and WHO grade II), gender, and patient age (<50 and ≥50 years of age). To evaluate  
119 relationships with survival, we selected 1 to 3 symptomatic patients matched to each IDG patient

120 on age at diagnosis (within 5 years), date of diagnosis (within 18 months), and tumor subtype  
121 (WHO grade II, III, and IV). Conditional Cox proportional hazards regression was used to  
122 estimate the Hazards Ratio (HR) and 95% CIs for IDG with adjustment via matching for age at  
123 diagnosis, date of diagnosis, and tumor subtype with observation beginning at first presentation  
124 of the tumor.

125

126

## 127 **Results**

128 A total of 32 of 1989 (1.6%) patients were asymptomatic from the tumor at diagnosis.  
129 Circumstances surrounding incidental glioma diagnosis are summarized in **Table 1**. The leading  
130 indications were non workplace-related injuries (n=7; examples: patient hit by a falling tree  
131 branch), followed by diagnoses made during medical work-up for unrelated diseases or  
132 conditions (n=6; examples: sleep apnea; progressive Parkinson's disease with dementia) and  
133 motor vehicle accidents in which the patient was not the driver or judged to be at fault (n=5;  
134 example: rear-ended by speeding car). Other categories included pre-operative workup for  
135 unrelated CNS surgery (n=1; pre-op for lumbar surgery); surveillance imaging after surgical  
136 repair of cerebral aneurysm (n=1, 6 month surveillance scan status-post left middle cerebral  
137 artery aneurysm clipping); examination for substance abuse (n=2; example: alcohol withdrawal  
138 and fentanyl overdose); infectious disease workup (n=2; viral meningitis and Epstein Barr  
139 mononucleosis); hypertension or diabetes workup (n=2; unexplained severe hypertension  
140 and uncontrolled diabetes); injury at work (n=2; example: hit in the head by falling box);  
141 peripheral neuropathy (n=1; neuropathy due to entrapment of ulnar nerve); unexplained dizziness  
142 (n=1; dizziness following brachytherapy for prostate cancer); infertility workup (n=1; related to  
143 increased levels of prolactin); and routine eye exam (n=1; papilledema observed during yearly  
144 eye exam in a patient with no noted symptoms).

145 Associations between symptom status at presentation and demographic and clinical factors are  
146 shown in **Table 2**. Prevalence of IDG was significantly higher in patients under 50 years of age  
147 (2.6%) than patients 50 years or older (1.0%). IDG was more common with progressively lower  
148 tumor grade: 0.6% for glioblastoma; 1.5% for WHO grade III; and 4.7% for WHO grade II. No

149 significant differences were observed by gender, race, state of residence, education, or  
150 hemispheric location of the tumor.

151 **Table 3** presents results from multivariable logistic regression considering factors associated  
152 with IDG. WHO grade II was associated with an over seven-fold increased prevalence of IDG  
153 (OR: 7.53; 95% CI: 2.87, 19.7) while controlling for gender and age. Neither age nor gender was  
154 independently associated with IDG after adjustment for tumor grade.

155 Results of conditional Cox proportional hazards regression of IDG in relation to tumor-related  
156 death are shown in **Table 4**. HRs were estimated among 28 IDG patients and 63 individually  
157 matched symptomatic patients. (No suitable match could be identified in 4 of the 32 IDG  
158 patients.) As shown in Table 4, the hazard of dying was significantly reduced by ~50% (HR:  
159 0.49; 95% CI: 0.26, 0.95;  $p=0.035$ ) in IDG adjusting through matching for age at diagnosis, date  
160 of diagnosis, and tumor subtype. Reduction in death rates was more pronounced when restricting  
161 to WHO grade II glioma (17 IDG and 36 symptomatic patients) (HR: 0.18; 95% CI: 0.03, 1.01;  
162  $p=0.051$ ) though results were based on limited data (1 death occurring among 17 IDG patients).

163 In 14 of 28 matched sets, the IDG patient and controls were concordant for resection (N=11 sets)  
164 or biopsy-only (N=3 sets) whereas the remaining 14 sets were discordant for extent of surgery  
165 (in 12 of the 14 sets, the IDG patient underwent resection whereas the controls underwent  
166 biopsy-only). When restricting to the 14 matched sets concordant for surgery (comprised of 6  
167 GBMs, 3 grade III gliomas, and 5 grade II gliomas), HRs were attenuated and no longer  
168 statistically significant (HR: 0.85; 95% CI: 0.42, 1.72;  $p=0.212$ ). Among the 5 matched sets  
169 comprised of WHO grade II gliomas, 0/5 IDG and 5/11 symptomatic patients died from glioma  
170 during the observation period.

## 171 **DISCUSSION**

172 The long-running clinic-based epidemiologic study, GliomaSE, offers a unique opportunity to  
173 describe the prognosis and natural history of subsets of patients with glioma. These subsets may  
174 offer insights as well as the generation of new hypotheses related to the course of these diseases.  
175 The study population is reflective of the population of patients with primary glioma diagnosed in  
176 the southeastern United States and genotyping of the study population has yielded results<sup>15,23</sup> in  
177 concordance with published glioma GWAS<sup>24</sup>.

178 In the present study, we observed that as many as 5% of grade II gliomas are asymptomatic at  
179 presentation. Tumor grade is an overwhelming predictor of IDG, with a 7.5-fold excess of IDG  
180 in grade II tumors and nonsignificant 2.4-fold excess in grade III tumors when compared to  
181 glioblastoma. IDG was unrelated to patient age or gender in multivariate regression analyses  
182 after adjustment for tumor grade. The present study raises the possibility that IDG is associated  
183 with a longer survival interval following presentation among grade II tumors only although only  
184 tentative conclusions can be reached given the limited number of IDG patients available for  
185 analysis.

186 Previous studies of IDG included tumors that came to attention during workup for headache<sup>18,25-</sup>  
187 <sup>27</sup>. We elected to exclude such cases as there was no instance in our series of a tumor detected in  
188 persons with a long-standing headache disorder during a purely ‘routine’ imaging study. Rather,  
189 headaches leading to diagnosis were described by such persons as acutely worsening or of a  
190 ‘different character’ as compared to headaches usually suffered by the patient and this in turn  
191 prompted diagnostic work-up and detection of the tumor. We therefore classified such patients as  
192 ‘symptomatic’.

193 The study had some limitations. In spite of the large patient series, suitable matches in the  
194 survival analyses were not identified for several of the IDG patients (4 of 32). Furthermore, only  
195 14 of the remaining 28 sets had controls matched also for tumor resection, a positive prognostic  
196 factor when compared to biopsy only<sup>11,12,28</sup>. When restricting analysis to these 14 matched sets  
197 concordant for surgery type (all members of the matched set undergoing resection or biopsy),  
198 reduced mortality in IDG patients was greatly attenuated (HR=0.85) (not shown). We note that  
199 the latter result was based predominately on higher grade tumors (9 of 14 pairs had a grade III  
200 astrocytoma or GBM), and it is possible that earlier detection via incidental diagnosis is  
201 associated with survival benefit only in low-grade tumors: as noted, among the 5 matched sets  
202 comprised of WHO grade II gliomas, 0/5 IDG and 5/11 symptomatic patients died from glioma  
203 during the observation period. Of note, a recent study published by Ius *et al* examining  
204 incidentally discovered low-grade gliomas did show that incidentally detected low grade gliomas  
205 had a longer overall survival than symptomatic low grade gliomas, even when a complete  
206 surgical resection was obtained<sup>27</sup>.

207 For most patients in this series, we lacked information on IDH mutation status which is a key  
208 prognostic feature of the low-grade tumors that comprised the majority of IDG patients in this  
209 study. (Most patients were diagnosed prior to the modern *IDH1* era). *IDH1* has been linked to  
210 improved patient survival<sup>8,29,30</sup>. In the present survival analysis, 39 of 91 patients had known  
211 *IDH1* status, and mutated *IDH1* was observed in a slightly higher proportion of IDG patients  
212 (52.9%, n=9 of 17) than non-IDG controls (40.9%, n=9 of 22) (p=0.43); among patients with  
213 WHO grade II tumors, 6/9 IDG and 4/10 symptomatic tumors were positive for *IDH1*.

214 Incidentalomas in GBM are rare and the potential impact on patient survival is poorly studied.  
215 Restricting to the 6 matched sets (5 GBM and 1 grade III astrocytoma) in which all members  
216 underwent resection within 3 months of tumor detection (mean: 27 days from presentation to  
217 surgery), IDG patients survived no longer (mean of 19.6 months; n=6) than the symptomatic  
218 patients (mean of 24.4 months; n=16); though based on limited data, these results suggest that  
219 incidental detection of the tumor does not extend survival in patients with high grade tumors.

220 The literature suggests that early identification of low-grade glioma is associated with  
221 improved outcomes as it is easier to operate on a smaller lesion<sup>10,31,32</sup>. In addition, by  
222 detecting tumor prior to the onset of neurological signs and symptoms the burden of disease is  
223 the least on a patient and the opportunity for preserved neurological function remains the  
224 highest. The difference in survival outcome in this report supports efforts to identify risk  
225 factors associated with glioma. There is increasing support for a moderate role of genetic  
226 susceptibility through the identification of risk alleles<sup>24</sup>. As further efforts define the  
227 biological significance of known risk variants and potentially expand this pool, genetic risk  
228 screening with targeted imaging may provide improved outcomes for patients, particularly the  
229 young adult with a low-grade glioma. This study provides some additional support for the  
230 developing evidence favoring early detection programs, “tailored screening,” and active  
231 management<sup>33</sup> which may include consideration of surgical resection, chemotherapy,  
232 radiotherapy, along with molecular and histopathologic characterization.

233

234

235

236

237

238

239

240

241

242

243

## 244 **References:**

- 245 1. DeAngelis LM. Brain Tumors. *N Engl J Med*. 2001;344(2):114-123.
- 246 2. Mandonnet E, de Witt Hamer P, Pallud J, Bauchet L, Whittle I, Duffau H. Silent diffuse low-grade  
247 glioma: Toward screening and preventive treatment? *Cancer*. 2014;120(12):1758-1762.
- 248 3. O’Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA. Prevalence and outcomes of incidental  
249 imaging findings: umbrella review. *BMJ*. 2018;361:k2387.
- 250 4. Katzman GL, Dagher AP, Patronas NJ. Incidental Findings on Brain Magnetic Resonance Imaging  
251 From 1000 Asymptomatic Volunteers. *JAMA*. 1999;282(1):36-39.
- 252 5. Morris Z, Whiteley WN, Longstreth WT, et al. Incidental findings on brain magnetic resonance  
253 imaging: systematic review and meta-analysis. *BMJ*. 2009;339:b3016.
- 254 6. Pallud J, Capelle L, Taillandier L, Badoual M, Duffau H, Mandonnet E. The silent phase of diffuse  
255 low-grade gliomas. Is it when we missed the action? *Acta neurochirurgica*. 2013;155(12):2237-  
256 2242.
- 257 7. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade  
258 glioma is a strong predictor for long-term survival. *Neuro Oncol*. 2013;15(4):469-479.
- 259 8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. *N Engl J Med*.  
260 2009;360(8):765-773.
- 261 9. Nabors LB, Portnow J, Ammirati M, et al. NCCN Guidelines Insights: Central Nervous System  
262 Cancers, Version 1.2017. *Journal of the National Comprehensive Cancer Network*.  
263 2017;15(11):1331-1345.
- 264 10. Duffau H. The Rationale to Perform Early Resection in Incidental Diffuse Low-Grade Glioma:  
265 Toward a “Preventive Surgical Neurooncology”. *World Neurosurgery*. 2013;80(5):e115-e117.
- 266 11. Jakola AS, Myrmet KS, Kloster R, et al. Comparison of a Strategy Favoring Early Surgical Resection  
267 vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas. *JAMA*. 2012;308(18):1881-1888.
- 268 12. McGirt MJ, Chaichana KL, Attenello FJ, et al. EXTENT OF SURGICAL RESECTION IS  
269 INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH HEMISPHERIC INFILTRATING  
270 LOW-GRADE GLIOMAS. *Neurosurgery*. 2008;63(4):700-708.
- 271 13. Compton JJ, Laack NNI, Eckel LJ, Schomas DA, Giannini C, Meyer FB. Long-term outcomes for  
272 low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic: Clinical article.  
273 *Journal of Neurosurgery*. 2012;117(5):825-830.
- 274 14. Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. *Acta*  
275 *neurochirurgica*. 2012;154(4):575-584.
- 276 15. Egan KM, Thompson RC, Nabors LB, et al. Cancer susceptibility variants and the risk of adult  
277 glioma in a US case-control study. *J Neurooncol*. 2011;104(2):535-542.
- 278 16. Lima GLdO, Zanella M, Mandonnet E, Taillandier L, Pallud J, Duffau H. Incidental diffuse low-  
279 grade gliomas: from early detection to preventive neuro-oncological surgery. *Neurosurg Rev*.  
280 2016;39(3):377-384.
- 281 17. Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of  
282 incidentally discovered low-grade gliomas: Clinical article. *Journal of Neurosurgery*.  
283 2012;116(2):365-372.
- 284 18. Wright E, Amankwah E, Winesett SP, et al. Incidentally found brain tumors in the pediatric  
285 population: a case series and proposed treatment algorithm. *Journal of neuro-oncology*. 2018.
- 286 19. Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental world health organization  
287 grade II gliomas. *Annals of Neurology*. 2010;68(5):727-733.
- 288 20. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO Classification of Tumours of the Central  
289 Nervous System. *Acta Neuropathol*. 2007;114(2):97-109.
- 290

- 291 21. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of  
292 Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131(6):803-820.  
293 22. Egan KM, Thompson RC, Nabors LB, et al. Cancer susceptibility variants and the risk of adult  
294 glioma in a US case-control study. *Journal of neuro-oncology.* 2011;104(2):535-542.  
295 23. Egan KM, Nabors LB, Olson JJ, et al. Rare TP53 genetic variant associated with glioma risk and  
296 outcome. *Journal of medical genetics.* 2012;49(7):420-421.  
297 24. Kinnersley B, Houlston RS, Bondy ML. Genome-Wide Association Studies in Glioma. *Cancer*  
298 *epidemiology, biomarkers & prevention : a publication of the American Association for Cancer*  
299 *Research, cosponsored by the American Society of Preventive Oncology.* 2018;27(4):418-428.  
300 25. Lim J, Park Y, Kim MJ, Ahn J, Cho Kg. SURG-31. INCIDENTAL LOW GRADE GLIOMAS: "WAIT AND  
301 SEE" OR "SURGERY". *Neuro Oncol.* 2017;19(suppl\_6):vi241-vi241.  
302 26. Opoku-Darko M, Lang S, Kelly J, Cadieux M. P.021 Surgical management of incidentally  
303 discovered diffusely infiltrating glioma. *Canadian Journal of Neurological Sciences.*  
304 2017;44(S2):S19-S19.  
305 27. Ius T, Cesselli D, Isola M, et al. Incidental Low-Grade Gliomas: Single-Institution Management  
306 Based on Clinical, Surgical, and Molecular Data. *Neurosurgery.* 2019.  
307 28. Berger MS, Rostomily RC. Low grade gliomas: Functional mapping resection strategies, extent of  
308 resection, and outcome. *Journal of neuro-oncology.* 1997;34(1):85-101.  
309 29. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and  
310 TERT Promoter Mutations in Tumors. *N Engl J Med.* 2015;372(26):2499-2508.  
311 30. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and  
312 response to temozolomide in low-grade gliomas. *Neurology.* 2010;75(17):1560-1566.  
313 31. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults: A review. *Journal of Neurosurgery.*  
314 2011;115(5):948-965.  
315 32. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the  
316 management of patients with diffuse low grade glioma. *Journal of neuro-oncology.*  
317 2015;125(3):503-530.  
318 33. Pouratian N, Schiff D. Management of low-grade glioma. *Current neurology and neuroscience*  
319 *reports.* 2010;10(3):224-231.

320

Table 1. Circumstances of incidental glioma diagnosis

Reason for incidental diagnosis	N (%)
Nonworkplace injury	7 (21)
Follow up for unrelated medical condition	6 (19)
Motor vehicle accident	5 (16)
Preoperative examination	2 (6)
Substance abuse examination	2 (6)
Infectious disease workup	2 (6)
Hypertension and/or diabetes workup	2 (6)
Workplace injury	2 (6)
Peripheral neuropathy workup	1 (3)
Unexplained dizziness	1 (3)
Infertility workup	1 (3)
Routine eye exam	1 (3)

Table 2. Descriptive statistics and symptoms at presentation in 1989 glioma patients

Variable	Level	Symptomatic at Presentation*		
		Yes (n=1957)	No (n=32)	p-value
Age at Diagnosis	<50	762 (97.4%)	20 (2.6%)	<b>0.01</b>
	≥ 50	1195 (99.0%)	12 (1.0%)	
Gender	Female	826 (98.7%)	11 (1.3%)	0.47
	Male	1131 (98.2%)	21 (1.8%)	
Race	Caucasian	1820 (98.3%)	31 (1.7%)	0.82
	African American	106 (99.0%)	1 (1.0%)	
	Asian or Pacific Islander	24 (100.0%)	0 (0.0%)	
State	AL	340 (98.8%)	4 (1.2%)	0.06
	FL	885 (98.1%)	17 (1.9%)	
	KY	158 (96.3%)	6 (3.7%)	
	Other	574 (99.1%)	5 (0.9%)	
Education	≤12 years	652 (98.2%)	12 (1.8%)	0.85
	>12 years	1183 (98.3%)	20 (1.7%)	
Hemisphere	Right	934 (98.2%)	17 (1.8%)	0.86
	Left	941 (98.5%)	14 (1.5%)	
	Bilateral	35 (97.2%)	1 (2.8%)	
Histology	GBM	1245 (99.4%)	8 (0.6%)	<b>&lt;0.01</b>
	Grade III	323 (98.5%)	5 (1.5%)	
	Grade II	389 (95.3%)	19 (4.7%)	

\*Unequal column totals reflect missing data

Table 3. Multivariate regression of clinical variates and asymptomatic presentation (N=1989)

Category	Exposure	No. asymptomatic	OR*	95% CI*	p-value
Tumor Grade	GBM	8	referent	-	-
	Grade III	5	2.41	(0.75, 7.68)	0.14
	Grade II	19	<b>7.53</b>	<b>(2.87,19.75)</b>	<b>&lt;0.01</b>
Gender	female	11	referent	-	-
	male	21	1.47	(0.70, 3.08)	0.31
Age at Dx	<50	20	referent	-	-
	>=50	12	0.96	(0.42, 2.23)	0.93

\*OR= odds ratio; CI=confidence interval. ORs/CIs adjusted for other terms included in the table.

Table 4. Association of asymptomatic presentation with survival in matched analysis

Parameter	HR	95% CI	P-Value
IDG vs. symptomatic gliomas <sup>1</sup>	0.49	(0.26, 0.95)	0.0349

Hazard ratio (HR) and 95% confidence interval (CI) for incidental glioma diagnosis (IDG) adjusted via matching for age at diagnosis (within 5 years), date of diagnosis (within 18 months), and tumor subtype (grade II, III or GBM). A total of 28 IDG and 63 individually-matched symptomatic patients were included in the analysis (no suitable match could be identified for the remaining 4 IDG patients).

